• 1
    Perry I, Neuberger J. Immunosuppression: towards a logical approach in liver transplantation. Clin Exp Immunol 2005; 139: 210.
  • 2
    Steininger R, Muhlbacher F, Hamilton G, Langle F, Gnant M, Popow T, et al. Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation. Transplant Proc 1991; 23: 22692271.
  • 3
    Furukawa H, Todo S. Evolution of immunosuppression in liver transplantation: contribution of cyclosporine. Transplant Proc 2004; 36(2 Suppl ): 274S284S.
  • 4
    Moser MA. Options for induction immunosuppression in liver transplant recipients. Drugs 2002; 62: 9951011.
  • 5
    Tector AJ, Fridell JA, Mangus RS, Shah A, Milgrom M, Kwo P, et al. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl 2004; 10: 404407.
  • 6
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 16; 130: 461470.
  • 7
    Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658663.
  • 8
    Ducloux D, Kazory A, Challier B, Coutet J, Bresson-Vautrin C, Motte G, et al. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study. Transplantation 2004 15; 77: 10291033.
  • 9
    Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 153154.
  • 10
    McVicar JP, Kowdley KV, Emond MJ, Barr D, Marsh CL, Carithers RL, et al. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation. Clin Transplant 1997; 11: 32833.
  • 11
    Wall WJ. Use of antilymphocyte induction therapy in liver transplantation. Liver Transpl Surg 1999; 5(4 Suppl 1 ): 6470.
  • 12
    Kamar N, Borde JS, Sandres-Saune K, Suc B, Barange K, Cointault O, et al. Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C. Clin Transplant 2005; 19: 8389.
  • 13
    Schulak J, May E, Post A, Fasola C, Mulligan D, Sterling R. Reduction of early rejection in adult liver transplantation with ATG induction therapy. Transplant Proc 1997; 29: 555556.
  • 14
    Guitard J, Cointault O, Kamar N, Muscari F, Lavayssiere L, Suc B, et al. Acute renal failure following liver transplantation with induction therapy. Clin Nephrol 2006; 65: 103112.
  • 15
    Lin CC, Chuang FR, Lee CH, Wang CC, Chen YS, Liu YW, et al. The renal-sparing effect of basiliximab in adult living donor liver transplantation. Liver Transpl 2005; 11: 12581264.
  • 16
    Tchervenkov JI, Tzimas GN, Cantarovich M, Barkun JS, Metrakos P. The impact of thymoglobulin on renal function and calcineurin inhibitor initiation in recipients of orthotopic liver transplant: a retrospective analysis of 298 consecutive patients. Transplant Proc 2004; 36: 17471752.
  • 17
    Mueller TF. Thymoglobulin: an immunologic overview. Curr Opin Organ Transpl 2003; 4: 305512.
  • 18
    Goggins WC, Pascual MA, Powelson JA, Magee C, Tolkoff-Rubin N, Farrell ML, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003 15; 76: 798802.
  • 19
    Neuhaus P, Klupp J, Langrehr JM, Neumann U, Gebhardt A, Pratschke J, et al. Quadruple tacrolimus-based induction therapy including azathioprine and ALG does not significantly improve outcome after liver transplantation when compared with standard induction with tacrolimus and steroids: results of a prospective, randomized trial. Transplantation 2000; 69: 23432353.
  • 20
    Jonas S, Rayes N, Neumann U, Neuhaus R, Bechstein WO, Guckelberger O, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997; 80: 11411150.